Study of Ruxolitinib in Pancreatic Cancer Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Pancreatic Cancer

In brief

The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.

Key facts

Study ID

NCT01423604

Run by

Incyte Corporation

People needed

136

Starts

2011-07-01

Expected to finish

2016-11-01

Last updated by the study team

2018-02-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Diagnosis of metastatic pancreatic cancer; subjects must have had measurable, or evaluable disease that was histologically confirmed
• Karnofsky performance status of ≥ 60
• Subjects must have failed 1st-line gemcitabine treatment for metastatic pancreatic cancer:
• o An alternate chemotherapeutic agent was an acceptable substitute as 1st-line therapy in the event that the subject was intolerant to or ineligible to receive gemcitabine
• ≥ 2 weeks elapsed from the completion of previous chemotherapy, and subjects must have recovered or been at new stable baseline from any related toxicities

You may not qualify if…

• More than 1 prior chemotherapy regimen (not including adjuvant therapy) for metastatic disease
• Evidence of central nervous system (CNS) metastases (unless stable for > 3 months) or history of uncontrolled seizures
• Ongoing radiation therapy or prior radiation therapy administered as a second-line treatment
• Other active malignancy except basal or squamous carcinoma of the skin
• Inability to swallow food or any condition of the upper GI tract that precluded administration of oral medications
• Inadequate renal, hepatic and bone marrow function demonstrated by clinical observations and/or laboratory assessments

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Hot Springs, Arkansas, United States
• Study site — Burbank, California, United States
• Study site — Los Angeles, California, United States
• Study site — Santa Monica, California, United States
• Study site — Denver, Colorado, United States
• Study site — Stamford, Connecticut, United States
• Study site — Boynton Beach, Florida, United States
• Study site — Fort Myers, Florida, United States
• Study site — St. Petersburg, Florida, United States
• Study site — Arlington Heights, Illinois, United States
• Study site — Elks Grove Village, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Sioux City, Iowa, United States
• Study site — Lexington, Kentucky, United States
• Study site — Louisville, Kentucky, United States
• Study site — Worcester, Massachusetts, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Detroit, Michigan, United States
• Study site — Grand Rapids, Michigan, United States
• Study site — Novi, Michigan, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — Voorhees Township, New Jersey, United States
• Study site — Albuquerque, New Mexico, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.